GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » ThermoGenesis Holdings Inc (STU:THR) » Definitions » Financial Strength

ThermoGenesis Holdings (STU:THR) Financial Strength : 1 (As of Mar. 2024)


View and export this data going back to . Start your Free Trial

What is ThermoGenesis Holdings Financial Strength?

ThermoGenesis Holdings has the Financial Strength Rank of 1. It displays poor financial strength and is likely in financial distress. Usually this is caused by too much debt for the company.

Warning Sign:

ThermoGenesis Holdings Inc displays poor financial strength. Usually, this is caused by too much debt for the company.

GuruFocus Financial Strength Rank measures how strong a company's financial situation is. It is based on these factors:

1. The debt burden that the company has as measured by its Interest Coverage (current year). The higher, the better.
2. Debt to revenue ratio. The lower, the better.
3. Altman Z-Score.

ThermoGenesis Holdings did not have earnings to cover the interest expense. ThermoGenesis Holdings's debt to revenue ratio for the quarter that ended in Mar. 2024 was 0.63. As of today, ThermoGenesis Holdings's Altman Z-Score is -41.61.


Competitive Comparison of ThermoGenesis Holdings's Financial Strength

For the Medical Devices subindustry, ThermoGenesis Holdings's Financial Strength, along with its competitors' market caps and Financial Strength data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


ThermoGenesis Holdings's Financial Strength Distribution in the Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, ThermoGenesis Holdings's Financial Strength distribution charts can be found below:

* The bar in red indicates where ThermoGenesis Holdings's Financial Strength falls into.



ThermoGenesis Holdings Financial Strength Calculation

GuruFocus Financial Strength Rank measures how strong a company's financial situation is. It is based on these factors

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

1. The debt burden that the company has as measured by its Interest Coverage (current year). The higher, the better.

Note: If both Interest Expense and Interest Income are empty, while Net Interest Income is negative, then use Net Interest Income as Interest Expense.

Interest Coverage is a ratio that determines how easily a company can pay interest expenses on outstanding debt. It is calculated by dividing a company's Operating Income (EBIT) by its Interest Expense:

ThermoGenesis Holdings's Interest Expense for the months ended in Mar. 2024 was €-1.34 Mil. Its Operating Income for the months ended in Mar. 2024 was €-0.51 Mil. And its Long-Term Debt & Capital Lease Obligation for the quarter that ended in Mar. 2024 was €2.50 Mil.

ThermoGenesis Holdings's Interest Coverage for the quarter that ended in Mar. 2024 is

ThermoGenesis Holdings did not have earnings to cover the interest expense.

The higher the ratio, the stronger the company's financial strength is.

2. Debt to revenue ratio. The lower, the better.

ThermoGenesis Holdings's Debt to Revenue Ratio for the quarter that ended in Mar. 2024 is

Debt to Revenue Ratio=Total Debt (Q: Mar. 2024 ) / Revenue
=(Short-Term Debt & Capital Lease Obligation + Long-Term Debt & Capital Lease Obligation) / Revenue
=(3.87 + 2.502) / 10.072
=0.63

3. Altman Z-Score.

Z-Score model is an accurate forecaster of failure up to two years prior to distress. It can be considered the assessment of the distress of industrial corporations.

The zones of discrimination were as such:

When Z-Score is less than 1.81, it is in Distress Zones.
When Z-Score is greater than 2.99, it is in Safe Zones.
When Z-Score is between 1.81 and 2.99, it is in Grey Zones.

ThermoGenesis Holdings has a Z-score of -41.61, indicating it is in Distress Zones. This implies bankrupcy possibility in the next two years.

Warning Sign:

Altman Z-score of -41.61 is in distress zone. This implies bankruptcy possibility in the next two years.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


ThermoGenesis Holdings  (STU:THR) Financial Strength Explanation

The maximum rank is 10. Companies with rank 7 or higher will be unlikely to fall into distressed situations. Companies with rank of 3 or less are likely in financial distress.

ThermoGenesis Holdings has the Financial Strength Rank of 1. It displays poor financial strength and is likely in financial distress. Usually this is caused by too much debt for the company.


ThermoGenesis Holdings Financial Strength Related Terms

Thank you for viewing the detailed overview of ThermoGenesis Holdings's Financial Strength provided by GuruFocus.com. Please click on the following links to see related term pages.


ThermoGenesis Holdings (STU:THR) Business Description

Traded in Other Exchanges
Address
2711 Citrus Road, Rancho Cordova, CA, USA, 95742
ThermoGenesis Holdings Inc develops, commercializes and markets a range of automated technologies for CAR-T and other cell-based therapies. The company currently markets a full suite of solutions for automated clinical biobanking, point-of-care applications, and automation for immuno-oncology, including its semi-automated, functionally-closed CAR-TXpress platform, which streamlines the manufacturing process for the emerging CAR-T immunotherapy market. It offers the AutoXpress and BioArchive platforms for automated clinical bio-banking, PXP platform for point-of-care cell-based therapies and CAR-TXpress platform for bio-manufacturing for immuno-oncology applications.